VolitionRx’s Nu.Q NETs biomarker shows predictive power in sepsis study

VolitionRx (VNRX) announced the results of a large-scale study which shows that its Nu.Q NETs H3.1 biomarker is an independent predictor of 28-day mortality and need for renal replacement therapy – RRT – in sepsis and septic shock patients. Findings published in the paper currently undergoing peer review and accessible on MEDRXIV, demonstrate Nu.Q NETs H3.1 is a promising novel biomarker for early mortality and organ dysfunction in sepsis, with significantly higher levels found in septic shock than sepsis patients and a clear dose-response relationship with acute kidney injury severity. The findings indicate Nu.Q NETs H3.1’s potential clinical utility for risk stratification and early intervention in critically ill patients presenting with sepsis. Volition is currently advancing several active commercial discussions with significant players in the diagnostic space, including large markets such as sepsis; the findings from the latest study support this ongoing licensing process.